Copanlisib dihydrochlorideProduct ingredient for Copanlisib

Name: Copanlisib dihydrochloride
Drug Entry: Copanlisib

Copanlisib is a selective pan-Class I phosphoinositide 3-kinase (PI3K) inhibitor with preferential activity against the alpha and delta isoforms. PI3K, a lipid kinase that activates downstream signalling pathways involved in cell survival and growth, that exists in different isoforms and is often overexpressed in hematological malignancies.² Copanlisib was granted accelerated approval by the FDA in September 2017 for the treatment of follicular lymphoma.¹

See full entry for Copanlisib
Accession Number: DBSALT002581
Structure: MOL SDF PDB SMILES InChI
Structure for Copanlisib dihydrochloride (DBSALT002581)
Synonyms: 2-Amino-N-{7-methoxy-8-[3-(morpholin-4-yl)propoxy]-2,3-dihydroimidazo[1,2-c]quinazolin-5-yl}pyrimidine-5-carboxamide dihydrochloride / 5-PYRIMIDINECARBOXAMIDE, 2-AMINO-N-(2,3-DIHYDRO-7-METHOXY-8-(3-(4-MORPHOLINYL)PROPOXY)IMIDAZO(1,2-C)QUINAZOLIN-5-YL)-, HYDROCHLORIDE (1:2) / BAY 80-6946 DIHYDROCHLORIDE / BAY-80-6946 DIHYDROCHLORIDE / Copanlisib Dihydrochloride / Copanlisib HCl / Copanlisib hydrochloride / COPANLISIB HYDROCHLORIDE ANHYDROUS
External IDs: BAY 80-6946 Dihydrochloride / BAY 84-1236 / BAY-80-6946 Dihydrochloride / BAY-84-1236